Evidence mapPaperPMID 41322383Full record

ArticleSchizophrenia research. Cognition2026

Diagnosis and management of cognitive impairment associated with schizophrenia: Real-world evidence from a cross-sectional survey of psychiatrists.

Stephanie H Read, Artak Khachatryan, Theresa A Cassidy

Abstract read
In one paragraph

Article in Schizophrenia research. Cognition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Stephanie H ReadCertara Drug Development Solutions, Certara, London, UK.
Artak KhachatryanCertara Drug Development Solutions, Certara, London, UK.
Theresa A CassidyBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cognitive impairment is a core feature of schizophrenia that can reduce functional capacity and quality of life in patients. However, it is unclear how physicians approach cognitive impairment associated with schizophrenia (CIAS) in real-world clinical practice. This study examines the knowledge, attitudes and practices of psychiatrists towards CIAS in patients. Methods: This non-interventional, cross-sectional study sampled psychiatrists across the US, UK and Germany with ≥36 months of clinical experience and who treated ≥5 patients with schizophrenia annually. Psychiatrists completed an online survey in December 2022 assessing their knowledge, attitudes and practices towards cognitive impairment in patients with schizophrenia. Outcome variables were analysed descriptively (patient estimates: median [IQR]; psychiatrist characteristics: n [%]). Results: Overall, 121 eligible psychiatrists completed the survey. Psychiatrists estimated that 50.0 % (28.0;80.0) of patients with schizophrenia exhibited cognitive impairment and diagnosed CIAS in 25.0 % (10.0;50.0) of patients. CIAS symptoms reportedly worsened over time and were transient in 50.0 % (30.0;70.0) and 20.0 % (10.0;30.0) of patients, respectively. Working and studying were ranked the activities of daily living most disrupted by CIAS by 48.8 % ( Conclusions: This study demonstrates limited consensus among psychiatrists regarding CIAS characterisation, diagnosis and management. These insights highlight an unmet need for effective diagnosis and treatment of CIAS, necessitating further research to improve the evidence base for clinical guidelines informing CIAS management.

Indexed as

Cognitive impairmentPatient characteristicsPsychiatristsReal-worldSchizophrenia

Identifiers

PMID41322383
PMCPMC12663012

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.